Completed Materials & Manufacturing Chemistry

Advanced flow technology for healthcare materials manufacturing

In plain English

AI plain-English summary

Gold nanoparticles and magnetic iron oxide nanoparticles could treat cancer and fight infections, but only if manufacturers can make them reliably in large quantities—and right now, they cannot. Today’s batch reactors mix ingredients poorly and control temperature unevenly, producing nanoparticles that vary from one batch to the next. This makes it impossible to scale up production for clinical use or to meet regulatory standards for consistency. The research team at University College London aims to design a continuous-flow manufacturing system that separates the stages of particle nucleation and growth, giving precise control over size, shape, and surface chemistry. They will combine materials chemistry with chemical engineering principles, working with industrial partners to test the nanoparticles in real applications. If the approach works, it could transform how high-value nanomaterials are made. Gold nanoparticles could be used for antimicrobial surfaces in hospitals, reducing infections. Magnetic nanoparticles could enable a new form of hyperthermia treatment for cancer, where particles are heated inside tumours to kill cancer cells. More broadly, the project aims to bridge the gap between laboratory discovery and commercial manufacturing—a step that currently stalls many promising nanotechnologies before they reach patients.

View original technical description
Inorganic nanoparticles have the potential to dramatically modify existing materials while providing the capability to engineer a broad range of transformative new products. Exhibiting unique properties not encountered in bulk materials, inorganic nanoparticles present the opportunity to address, and the potential to overcome, some of the most pressing global challenges. This is leading to intense global competition to develop and commercialize nanoproducts with a variety of applications in healthcare, energy, transport and security, with the aim of acquiring a dominant market position in the nanotechnology sector. Nanoparticles offer ideal solutions for detecting and treating many diseases. They can be used as drug carriers, labelling and tracking agents, and vectors for gene therapy, hyperthermia treatment and magnetic resonance imaging contrast agents. Used as targeted drug-delivery systems, they can improve the performance of medicines already on the market. They enable the development of new therapeutic strategies such as anti-cancer drug delivery, extending product life cycles and reducing healthcare costs. In this proposal we focus on the manufacturing of gold nanoparticles (Au-NPs) and iron oxide magnetic nanoparticles (MNPs). These materials have existing applications in diagnostics and therapeutics. Bespoke monodispersed functionalised NPs offer new applications in antimicrobial surfaces (Au NPs plus dye) and in a new hyperthermia treatment for cancer (MNPs). UCL is at the forefront of the engineering approach to make nanoparticles as well as being world leading in magnetic hyperthermia and antimicrobial surfaces. Nanoparticles are conventionally synthesized in relatively small batch reactors. These systems are poorly controllable, leading to products that are hard to reproduce. Also, they do not lend themselves to expedient upscaling. Such problems are caused by the inefficient mixing and slow heat and mass transfer characterizing batch reactors, and by the difficulty of decoupling in time the various stages of the synthesis, particularly particle nucleation and growth. This research aims to design and demonstrate a new, sustainable and scalable approach for manufacturing high-value nanomaterials with advanced properties in a way that is controllable and reproducible and that does not involve significant upscaling issues. To attain this ambitious goal, we will integrate methods, skills and strengths of different disciplines (materials chemistry, engineering), seeking guidance from industrial partners and UK manufacturing centres. Giving us access to their state-of-the-art facilities, sharing their expertise and providing an application context for our work, they will further characterize the nanoparticles, evaluate their performance and facilitate pathways to manufacture and routes to market. There is currently a lot of research in developing novel materials, where the focus is on discovery but with little emphasis on manufacturing. Using chemical engineering principles and systems engineering methodologies within a multidisciplinary framework, our research will demonstrate not only the need to consider key physical phenomena (mixing, heat transfer etc.) in nanoparticles synthesis, but also how to account and address related manufacturing challenges from the outset. In this way, an important benefit of this project will be to provide a paradigm shift in nanoparticle synthesis and production and bridge the discovery-manufacturing divide.

View the original record at the funder ↗

Researchers

Alan Jones (Co-Investigator)Asterios Gavriilidis (Principal Investigator)Charalampos Makatsoris (Co-Investigator)Ivan Parkin (Co-Investigator)Junwang Tang (Co-Investigator)Luca Mazzei (Co-Investigator)Paola Lettieri (Co-Investigator)Quentin Pankhurst (Co-Investigator)THANH NGUYEN (Co-Investigator)Vivek Dua (Co-Investigator)

Related Research

Grants with similar aims, by meaning.

Materials World Network: The Designer Nanoparticle
Dial-a-particle: model-driven self-optimised manufacturing platform of nanoparticles
NanoMan: Self-Optimising Nanoscale Manufacturing Platforms for Achieving Multiscale Precision
Magnetic nanoparticle engineering via microreaction technology
Enabling manufacturing of Functional Nanomaterials using SynBio

Original classification

Research Grant

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.